Development of an anti-GM1 antibody-specific glycomimetic for Guillain-Barré syndrome and multifocal motor neuropathy
Year: 2026
Type: article
Abstract: Multifocal motor neuropathy (MMN) is a chronic autoimmune neuropathy predominately affecting motor neurons, caused by IgM antibodies that target the ganglioside GM1. These pathogenic autoantibodies trigger complement-mediated nodal disruption and axonal injury at paranodes and neuromuscular junctions. Similar anti-GM1 antibodies also drive acute forms of peripheral neuropathy, such as Guillain-Barré-Syndrome (GBS), in which molecular mimicry following infection induces cross-reactive immune responses. Antibodies generated against microbial GM1-like glycans bind endogenous GM1, leading to severe neurological symptoms which requires intensive care. Current therapies, such as plasmapheresis and intravenous immunoglobulins (IVIG), can be effective, however, they lack selectivity and can cause adverse effects. We hypothesize that selective depletion of autoreactive anti-GM1 antibodies could provide a targeted therapeutic strategy. This antibody removal can be achieved through multivalent presentation of carbohydrate mimetics of pentasaccharide on a biodegradable poly- l -lysine scaffold. Here we report the development of a lead compound that successfully inhibits binding of anti-GM1 antibodies from patients’ sera to GM1 and effectively prevents binding of anti-GM1 antibodies on terminal axonal networks in vitro and ex vivo.
Source: Scientific Reports
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7233593783
FWCI:
Cites:
Cited by:
Related to:
